Neurogene Inc. Interest Income (Expense), Net
Neurogene Inc. (NGNE) reported Interest Income (Expense), Net of $1.04 million for the 3-month period ending 2023-09-30, per its 10-Q filed 2023-11-14.
Discontinued › Income Statement › Other Income
us-gaap:InterestIncomeExpenseNet · last filed 2023-11-14
- Neurogene Inc. interest income (expense), net for the quarter ending 2023-09-30 was $1.04M, a 86.58% increase year-over-year.
- Neurogene Inc. interest income (expense), net for the quarter ending 2023-06-30 was $981.00K, a 405.67% increase year-over-year.
- Neurogene Inc. interest income (expense), net for the quarter ending 2023-03-31 was $945.00K, a 7169.23% increase year-over-year.
- Neurogene Inc. interest income (expense), net for the quarter ending 2022-12-31 was $816.00K, a 16220.00% increase year-over-year.
- Neurogene Inc. interest income (expense), net for fiscal 2022 was $1.58M, a 8226.32% increase from fiscal 2021.
- Neurogene Inc. interest income (expense), net for fiscal 2021 was $19.00K.
| Period end | Interest Income (Expense), Net 3 month | Interest Income (Expense), Net 6 month | Interest Income (Expense), Net 9 month | Interest Income (Expense), Net 12 month |
|---|---|---|---|---|
| 2023-09-30 | $1.04M 10-Q · filed 2023-11-14 | $2.02M derived: sum of 2 quarters · filed 2023-11-14 | $2.97M 10-Q · filed 2023-11-14 | $3.79M derived: sum of 4 quarters · filed 2023-11-14 |
| 2023-06-30 | $981.00K 10-Q · filed 2023-08-10 | $1.93M 10-Q · filed 2023-08-10 | $2.74M derived: sum of 3 quarters · filed 2023-08-10 | $3.30M derived: sum of 4 quarters · filed 2023-11-14 |
| 2023-03-31 | $945.00K 10-Q · filed 2023-05-08 | $1.76M derived: sum of 2 quarters · filed 2023-05-08 | $2.32M derived: sum of 3 quarters · filed 2023-11-14 | $2.51M derived: sum of 4 quarters · filed 2023-11-14 |
| 2022-12-31 | $816.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-20 | $1.38M derived: sum of 2 quarters · filed 2023-11-14 | $1.57M derived: sum of 3 quarters · filed 2023-11-14 | $1.58M 10-K · filed 2023-03-20 |
| 2022-09-30 | $559.00K 10-Q · filed 2023-11-14 | $753.00K derived: sum of 2 quarters · filed 2023-11-14 | $766.00K 10-Q · filed 2023-11-14 | $771.00K derived: sum of 4 quarters · filed 2023-11-14 |
| 2022-06-30 | $194.00K 10-Q · filed 2023-08-10 | $207.00K 10-Q · filed 2023-08-10 | $212.00K derived: sum of 3 quarters · filed 2023-08-10 | $218.00K derived: sum of 4 quarters · filed 2023-08-10 |
| 2022-03-31 | $13.00K 10-Q · filed 2023-05-08 | $18.00K derived: sum of 2 quarters · filed 2023-05-08 | $24.00K derived: sum of 3 quarters · filed 2023-05-08 | |
| 2021-12-31 | $5.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-20 | $11.00K derived: sum of 2 quarters · filed 2023-03-20 | $19.00K 10-K · filed 2023-03-20 | |
| 2021-09-30 | $6.00K 10-Q · filed 2022-11-14 | $14.00K 10-Q · filed 2022-11-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |